Johnson Matthey Catalysis and Chiral Technologies Expands Ligands Offer; Boosts Buchwald Ligands Manufacturing to Commercial Scale
Matthey (LSE: JMAT) has announced that their global Catalysis and Chiral Technologies technology business unit, JMCCT, which provides trusted expertise in heterogeneous, homogeneous, chiral and biocatalytic technologies for customers in the pharmaceutical, fine chemical and agrochemical industries, is expanding its existing specialty ligand manufacturing capability to include commercial-scale manufacturing up to 100kg.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.